| Management of sunitinib adverse events in renal cell carcinoma patients: The Asian experience. | |
| | |
MedLine Citation:
|
PMID: 22524572 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Sunitinib is the gold standard of care for patients with metastatic renal cell carcinoma, demonstrating an overall survival benefit of over 2 years in a pivotal phase 3 trial of 750 patients. While sunitinib is generally well tolerated with most adverse events, manifesting as mild to moderate in severity and manageability, it has a distinctive adverse event profile that benefits from careful monitoring during treatment. As sunitinib gains widespread use across the globe, best practices are being developed for specific patient groups. This review will focus on the current clinical trial data in Asian populations and on the mechanism, incidence and management of selected sunitinib-related adverse events, including hand-foot syndrome, hypertension, proteinuria, cardiac toxicities, myelosupression, fatigue/asthenia, hypothyroidism, diarrhea and hepatotoxicity. Taken together, the developing body of literature reviewed here demonstrates that sunitinib is well tolerated in Asian patients and provides efficacy that is similar, if not superior, to other patient groups. Asian patients, like all patients, should begin treatment of sunitinib at 50 mg on Schedule 4/2 (4 weeks on treatment/2 weeks off). Prophylactic measures, good communication between patient and health-care providers, and early, aggressive intervention at the development of adverse events can limit the dose reductions required and maximize both patients' response to treatment and their quality of life. |
| | |
Authors:
|
Aiping Zhou |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Asia-Pacific journal of clinical oncology Volume: 8 ISSN: 1743-7563 ISO Abbreviation: Asia Pac J Clin Oncol Publication Date: 2012 Jun |
Date Detail:
|
Created Date: 2012-04-24 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101241430 Medline TA: Asia Pac J Clin Oncol Country: Australia |
Other Details:
|
Languages: eng Pagination: 132-44 Citation Subset: IM |
Copyright Information:
|
© 2012 Blackwell Publishing Asia Pty Ltd. |
Affiliation:
|
Peking Union Medical College, Beijing, China. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Primary nasopharyngeal adenocarcinoma: A review.
Next Document: Triple-negative breast cancer: making the most of a misnomer.